Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care

Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic stress disorder and treatment-resistant depression. Here, we briefly explore the history of its use, how it works, and the hope it may provide people receiving end-of-life care.